Drug Trial Radar · NCT04102579
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Last checked: Nov 20, 2026Latest source record: Oct 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Nov 13, 2019
Primary completion
Oct 15, 2021
Study completion Oct 26, 2021
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- Collaborators
- Huntington Study Group
- First posted
- Sep 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
Conditions
- Chorea, Huntington
Interventions
ValbenazineDrug
vesicular monoamine transporter 2 (VMAT2) inhibitor
PlaceboDrug
non-active dosage form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Screening Period Baseline to Maintenance Period in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score.Time frame: Baseline (average of screening and Day -1), maintenance (average of Weeks 10 and 12)
Locations
46 sites in 2 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Birmingham, Alabama
Neurocrine Clinical Site
Little Rock, Arkansas
Neurocrine Clinical Site
La Jolla, California
Neurocrine Clinical Site
Sacramento, California
Neurocrine Clinical Site
Aurora, Colorado
Neurocrine Clinical Site
Englewood, Colorado
Neurocrine Clinical Site
Washington D.C., District of Columbia
Neurocrine Clinical Site
Gainesville, Florida
Neurocrine Clinical Site
Miami, Florida
Neurocrine Clinical Site
Atlanta, Georgia
Neurocrine Clinical Site
Chicago, Illinois
Neurocrine Clinical Site
Chicago, Illinois
Neurocrine Clinical Site
Indianapolis, Indiana
Neurocrine Clinical Site
Iowa City, Iowa
Neurocrine Clinical Site
Kansas City, Kansas
Neurocrine Clinical Site
Wichita, Kansas
Neurocrine Clinical Site
Louisville, Kentucky
Neurocrine Clinical Site
New Orleans, Louisiana
Neurocrine Clinical Site
Boston, Massachusetts
Neurocrine Clinical Site
Boston, Massachusetts
Neurocrine Clinical Site
Charlestown, Massachusetts
Neurocrine Clinical Site
Ann Arbor, Michigan
Neurocrine Clinical Site
West Bloomfield, Michigan
Neurocrine Clinical Site
Omaha, Nebraska
Neurocrine Clinical Site
Rochester, New York
Neurocrine Clinical Site
Williamsville, New York
Neurocrine Clinical Site
Durham, North Carolina
Neurocrine Clinical Site
Fargo, North Dakota
Neurocrine Clinical Site
Cleveland, Ohio
Neurocrine Clinical Site
Columbus, Ohio
Neurocrine Clinical Site
Toledo, Ohio
Neurocrine Clinical Site
Pittsburgh, Pennsylvania
Neurocrine Clinical Site
Charleston, South Carolina
Neurocrine Clinical Site
Columbia, South Carolina
Neurocrine Clinical Site
Greenville, South Carolina
Neurocrine Clinical Site
Nashville, Tennessee
Neurocrine Clinical Site
Houston, Texas
Neurocrine Clinical Site
Salt Lake City, Utah
Neurocrine Clinical Site
Burlington, Vermont
Neurocrine Clinical Site
Charlottesville, Virginia
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.